Election May Determine Pace of Biosimilar Legislation
There are several pending legislative proposals in both the House of Representatives and the Senate designed to encourage more commercialization of biosimilars, but the 2020 election may determine their timing.
Pending Antitrust Actions Could Change Biosimilar Dynamics
Depending on the outcome, 3 major biosimilar antitrust actions, as well as a related Federal Trade Commission investigation, could significantly change how biologics are priced.
2 Clarke Drive Cranbury, NJ 08512